Dr. Susie Dilly, CEO of ValiSeek, provides an update on the clinical development of its novel cancer treatment drug, VAL401. ValiSeek confirms that it has received positive opinion and approval from the ethics committee, a significant step in the regulatory process prior to patient recruitment and dosing.